Abstract:1134 Objectives: Liposome, as a FDA proved nano-sized drug carrier material with excellent biodegradability and biocompatibility, has been extensively used in tumor chemotherapy. Liposomes not only can encapsulate small drug molecules or signaling molecules, but also can be easily and conveniently modified externally, which is an unique advantage for developing multifunctional and theranostic nanoparticle probes. Liposomes have been radiolabeled and applied mostly for tumor detection, but very rarely for radiotherapy. Herein, 177Lu-labeled DiR-encapsulated liposome was evaluated for SPECT/Optical dual-modality imaging and biodistribution in Lewis lung cancer (LLC) xenografts. Furthermore, the therapeutic efficacy of 177Lu-labeled Dox-encapsulated liposome for combination radio-chemotherapy was firstly assessed in LLC xenografts. Methods: Biodistribution, SPECT/Optical dual-modality imaging and maximum tolerated dose (MTD) studies of 177Lu-Liposome were performed. The radiotherapy studies were begun when the tumor reached 50~80 mm3 and were compared with liposome encapsulated Doxorubicin or in combination. The liposome encapsulated Doxorubicin was given once every three days for three times totally. Tumor size and body weight were monitored every other day. When the tumor volume reached 1500 mm3 or more than 20% of the weight loss, the experiment was concluded. Results: 177Lu-Liposome are slowly cleared from the blood and at 24 h post-injection, tumor uptake reached the highest (7.55 ± 3.85%ID/g); until 72 h post-injection, the tumor is still maintaining a high uptake (5.02 ± 2.75%ID/g). The tumors were clearly visualized by the SPECT/Optical imaging. Compared with liposome encapsulated Doxorubicin alone, the 177Lu-liposome or the combination of 177Lu-liposome with doxorubicin has further notably inhibited tumor growth. From the fifth day post-treatment, the combination therapy of 177Lu-Dox-liposome has an enhanced inhibition of tumor growth than that of Dox-liposome or 177Lu-liposome, and this advantage has been maintained until the experiment was concluded. Conclusions: The 177Lu-radiolabeled payloaded liposome was prepared as a multifunctional nanoprobe. Passive targeted therapy of 177Lu-liposome is effective in LLC tumor model. 177Lu-liposome radiotherapy alone or combination with Dox-liposome, can remarkably suppress the tumor growth in LLC tumor model. Development of the multimodality imaging nanoprobe and its potential for the diagnosis and treatment is in progress.

<SUP>131</SUP>I-labeled and DOX-loaded multifunctional nanoliposomes for radiotherapy and chemotherapy in brain gliomas

131I-Labeled and DOX-loaded Multifunctional Nanoliposomes for Radiotherapy and Chemotherapy in Brain Gliomas

Interpreting the Therapeutic Efficiency of Multifunctional Hybrid Nanostructure Against Glioblastoma

Lactoferrin Modified Doxorubicin-Loaded Procationic Liposomes for the Treatment of Gliomas

Doxorubicin and indocyanine green loaded superparamagnetic iron oxide nanoparticles with PEGylated phospholipid coating for magnetic resonance with fluorescence imaging and chemotherapy of glioma

Doxorubicin-Loaded Liposome with the Function of "Killing Two Birds with One Stone" against Glioma

Synergistic Combination of Doxorubicin and Paclitaxel Delivered by Blood Brain Barrier and Glioma Cells Dual Targeting Liposomes for Chemotherapy of Brain Glioma.

Lactoferrin/phenylboronic Acid-Functionalized Hyaluronic Acid Nanogels Loading Doxorubicin Hydrochloride for Targeting Glioma.

Glucose and Triphenylphosphonium Co-Modified Redox-Sensitive Liposomes to Synergistically Treat Glioma with Doxorubicin and Lonidamine

iRGD Modified Chemo‐immunotherapeutic Nanoparticles for Enhanced Immunotherapy against Glioblastoma

Multiple targeted doxorubicin-lonidamine liposomes modified with p-hydroxybenzoic acid and triphenylphosphonium to synergistically treat glioma

Theranostic Nanomedicine for Synergistic Chemodynamic Therapy and Chemotherapy of Orthotopic Glioma

LDLR-mediated Peptide-22-conjugated Nanoparticles for Dual-Targeting Therapy of Brain Glioma.

A Targeted and Responsive Nanoprodrug Delivery System for Synergistic Glioma Chemotherapy

Combined Therapeutic Effects of 131I-Labeled and 5Fu-Loaded Multifunctional Nanoparticles in Colorectal Cancer.

Lu-177-labeled Payloaded Liposome for SPECT/Optical Dual-modality Imaging and Combined Radio- and Chemotherapy in LLC Mice Model

Nanostructured Lipid Carrier Co-Delivering Paclitaxel And Doxorubicin Restrains The Proliferation And Promotes Apoptosis Of Glioma Stem Cells Via Regulating Pi3k/Akt/Mtor Signaling

Targeting therapeutic effect of radioiodine-labeled anti-EGFR binding nanoparticles on glioblastoma cells

Transferrin-modified Doxorubicin-loaded biodegradable nanoparticles exhibit enhanced efficacy in treating brain glioma-bearing rats.

Smart multifunctional core-shell nanospheres with drug and gene co-loaded for enhancing the therapeutic effect in a rat intracranial tumor model.

Active targeted delivery of theranostic thermo/pH dual-responsive magnetic Janus nanoparticles functionalized with folic acid/fluorescein ligands for enhanced DOX combination therapy of rat glioblastoma